Download PDF - The Dermatologist

FA L L C L I N I C A L D E R M AT O L O G Y C O N F E R E N C E P R O C E E D I N G S
FIGURE 4. ERYTHEMA OF ROSACEA: A 41-YEAR-OLD WOMAN WITH PERSISTENT ERYTHEMA OF
ROSACEA BASELINE AND AFTER 4 WEEKS OF MIMYX TWICE DAILY.
BASELINE
AFTER 4 WEEKS
and stratum corneum tryptic enzymes, which lead to
abnormal peptides and the signs and symptoms of
rosacea. They discovered increased levels of cathelicidin
A NEW AREA OF RESEARCH FOR
ROSACEA THAT APPEARS PROMISING
IS DETERMINING THE ROLE OF
CATHELICIDINS AND TRYPTIC
ENZYMES AND THEIR POSSIBLE
ASSOCIATIONS WITH ROSACEA.
and diff e rent cathelicidins in patients who have ro s a c e a
versus those who do not have rosacea, and these peptides
can lead to inflammation, which can be blocked by
the use of antibiotics. Further study is warranted to
determine how decreasing cathelicidin will advance
rosacea therapy.
C O N C L U S I O N
Few new medications have been developed for the tre a t-
ment of rosacea in recent years; however, even the newest
rosacea treatment will not be effective if the patient does not
have rosacea. In treating cases of suspected rosacea, it is
important for the dermatologist to consider the diff e re n t i a l
diagnoses, such as seborrheic dermatitis and irritant/allergic
contact dermatitis, and also to be aware of unusual pre s e n t a-
tions of rosacea, such as plaque rosacea. Basic skin care
remains essential in the treatment of patients with ro s a c e a ,
and new products that have become available over the counter
offer patients a wider variety from which to choose. Finally,
further re s e a rch on the role of cathelicidin in rosacea may provide
dermatologists new treatment options in the future.
References
1. van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic
review of rosacea treatments. J Am Acad Dermatol. 2007;56(1):107–115.
2. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III
clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline,
USP capsules) administered once daily for treatment of rosacea. J Am
Acad Dermatol. 2007;56(5):791–802.
3. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity
and cathelicidin promotes skin inflammation in rosacea. Nat Med.
2007;13(8):975–980.
S U P P L E M E N T T O S K I N & A G I N G • M A R C H 2 0 0 8 • 1 1